633 results on '"Burnett, John C. Jr."'
Search Results
2. Prognostic Value of Urinary and Plasma C-Type Natriuretic Peptide in Acute Decompensated Heart Failure
3. STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure
4. Renal Outcomes in Patients with Systolic Heart Failure Treated With Sacubitril-Valsartan or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker
5. Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction
6. Mechanisms of Cardiorenal Syndrome: From Molecular Pathways to Novel Therapeutics
7. Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position Paper
8. Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction
9. Cardiac Versus Renal Response to Volume Expansion in Preclinical Systolic Dysfunction With PDEV Inhibition and BNP
10. Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure
11. Differential Regulation of ANP and BNP in Acute Decompensated Heart Failure: Deficiency of ANP
12. Discovery of O-glycans on atrial natriuretic peptide (ANP) that affect both its proteolytic degradation and potency at its cognate receptor
13. C53: A novel particulate guanylyl cyclase B receptor activator that has sustained activity in vivo with anti-fibrotic actions in human cardiac and renal fibroblasts
14. Natriuretic peptide based therapeutics for heart failure: Cenderitide: A novel first-in-class designer natriuretic peptide
15. MANP: A natriuretic peptide-based therapy for cardiometabolic disease
16. The Endocrine Heart
17. Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population
18. Innovative Therapeutics: Designer Natriuretic Peptides
19. Chronic Peptide Therapy With B-Type Natriuretic Peptide in Patients With Pre-Clinical Diastolic Dysfunction (Stage B Heart Failure)
20. Effect of Neurohormonal Blockade Drug Therapy on Outcomes and Left Ventricular Function and Structure After Left Ventricular Assist Device Implantation
21. Cardiorenal fibrosis and dysfunction in aging: Imbalance in mediators and regulators of collagen
22. Pro–Atrial Natriuretic Peptide: A Novel Guanylyl Cyclase-A Receptor Activator That Goes Beyond Atrial and B-Type Natriuretic Peptides
23. Urinary C-type natriuretic peptide: An emerging biomarker for heart failure and renal remodeling
24. Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones:biomarkers or mediators
25. In Vitro Evaluation of Cenderitide‐Eluting Stent I —An Antirestenosis and Proendothelization Approach
26. Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: Regulation and therapeutic implications
27. Kidney in Acute Heart Failure
28. GPCR biased ligands as novel heart failure therapeutics
29. Endothelial permeability in vitro and in vivo: Protective actions of ANP and omapatrilat in experimental atherosclerosis
30. Rationale and Design of a Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of B-Type Natriuretic Peptide for the Preservation of Left Ventricular Function After Anterior Myocardial Infarction
31. Secretion of Prohormone of B-Type Natriuretic Peptide, proBNP1-108, Is Increased in Heart Failure
32. Urinary C-Type Natriuretic Peptide: A New Heart Failure Biomarker
33. Variable phenotype in murine transverse aortic constriction
34. The Heart Failure Society of America in 2020: A Vision for the Future
35. Natriuretic Peptides in Cardiovascular Disease : A Focus on Congestive Heart Failure
36. C-Type Natriuretic Peptide : The Vascular Component of the Natriuretic Peptide System
37. Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: Analysis from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Trials
38. Utility of Doppler Myocardial Imaging, Cardiac Biomarkers, and Clonal Immunoglobulin Genes to Assess Left Ventricular Performance and Stratify Risk Following Peripheral Blood Stem Cell Transplantation in Patients with Systemic Light Chain Amyloidosis (AL)
39. Predictive Utility of Atrial, N-Terminal Pro-Atrial, and N-Terminal Pro-B-Type Natriuretic Peptides for Mortality and Cardiovascular Events in the General Community: A 9-Year Follow-up Study
40. The Effect of the Brain-Type Natriuretic Peptide Single-Nucleotide Polymorphism rs198389 on Test Characteristics of Common Assays
41. Angiotensin Receptors and Renal Function
42. Natriuretic peptide pharmacogenetics: Membrane metallo-endopeptidase (MME): Common gene sequence variation, functional characterization and degradation
43. Coupling of a vented column with splitless nanoRPLC-ESI-MS for the improved separation and detection of brain natriuretic peptide-32 and its proteolytic peptides
44. Natriuretic Peptides in the Diagnosis and Management of Chronic Heart Failure
45. Role for precursor Pro-B type natriuretic peptide in assessing response to therapy and prognosis in patients with decompensated heart failure treated with nesiritide
46. Prognostic Value of Multiple Biomarkers in American Indians Free of Clinically Overt Cardiovascular Disease (from the Strong Heart Study)
47. Novel Bifunctional Natriuretic Peptides as Potential Therapeutics
48. B-Type Natriuretic Peptide: Beyond a Diagnostic
49. The Effects of Nesiritide on Renal Function and Diuretic Responsiveness in Acutely Decompensated Heart Failure Patients With Renal Dysfunction
50. Cardiac Resynchronization Therapy Improves Renal Function in Human Heart Failure With Reduced Glomerular Filtration Rate
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.